NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis $12.16 -0.03 (-0.25%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immatics alerts: Email Address About Immatics Stock (NASDAQ:IMTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immatics alerts:Sign Up Key Stats Today's Range$12.10▼$12.5150-Day Range$10.93▼$12.9252-Week Range$7.15▼$13.77Volume179,073 shsAverage Volume461,736 shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingBuy Company OverviewImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More… “Buffett Indicator” Predicts 62% Stock Market Crash (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Immatics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 37th PercentileImmatics scored higher than 37% of companies evaluated by MarketBeat, and ranked 747th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmatics has only been the subject of 1 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($0.99) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.31% of the outstanding shares of Immatics have been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 31.2, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently increased by 1.17%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.31% of the outstanding shares of Immatics have been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 31.2, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently increased by 1.17%, indicating that investor sentiment is decreasing. News and Social Media3.0 / 5News Sentiment0.49 News SentimentImmatics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Immatics this week, compared to 1 article on an average week.Search Interest7 people have searched for IMTX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows1 people have added Immatics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address IMTX Stock News HeadlinesFY2024 Earnings Estimate for Immatics Issued By Leerink Partnrs (NASDAQ:IMTX)September 19 at 7:21 AM | americanbankingnews.comImmatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development UpdateSeptember 16 at 5:25 AM | globenewswire.com“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.September 19, 2024 | InvestorPlace (Ad)Leerink Partners Remains a Buy on Immatics (IMTX)September 11, 2024 | markets.businessinsider.comImmatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024September 6, 2024 | globenewswire.comImmatics Second Quarter 2024 Earnings: Beats ExpectationsAugust 16, 2024 | finance.yahoo.comBuy Rating for Immatics: Promising Clinical Trials and Strong Financials Signal Upside PotentialAugust 16, 2024 | markets.businessinsider.comBuy Rating Justified by Immatics’ Advancing Pipeline and Strategic Financial PositionAugust 16, 2024 | markets.businessinsider.comSee More Headlines IMTX Stock Analysis - Frequently Asked Questions How have IMTX shares performed this year? Immatics' stock was trading at $10.53 on January 1st, 2024. Since then, IMTX shares have increased by 15.5% and is now trading at $12.16. View the best growth stocks for 2024 here. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.17. The business earned $20.19 million during the quarter, compared to the consensus estimate of $12.36 million. Immatics had a negative net margin of 103.99% and a negative trailing twelve-month return on equity of 23.34%. Who are Immatics' major shareholders? Top institutional investors of Immatics include Perceptive Advisors LLC (9.55%), Frazier Life Sciences Management L.P. (1.36%), Sofinnova Investments Inc. (0.94%) and TD Asset Management Inc (0.42%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX) and Company Calendar Last Earnings8/13/2024Today9/19/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+31.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,980,000.00 Net Margins-103.99% Pretax Margin-101.82% Return on Equity-23.34% Return on Assets-13.22% Debt Debt-to-Equity RatioN/A Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$70.87 million Price / Sales14.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book4.24Miscellaneous Outstanding Shares84,658,000Free Float81,864,000Market Cap$1.03 billion OptionableOptionable Beta0.75 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:IMTX) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | SponsoredThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.